ARTICLE | Company News
Management tracks: Mittal to succeed Biocon’s Chandavarkar; plus Intercept, Nektar, Agios, Accelerate, ABPI and more
December 4, 2019 11:57 PM UTC
Updated on Dec 11, 2019 at 2:34 AM UTC
CFO Siddharth Mittal will succeed Arun Chandavarkar as CEO and joint managing director of Biocon Ltd. (NSE:BIOCON; BSE:532523). Chandavarkar, who retired last month, had been with the Indian biopharma since 1990. Mittal joined in 2013 and became CFO the following year.
Liver disease company Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) promoted Jason Campagna to CMO from SVP and NASH program leader. He succeeds David Shapiro, who retired in May...